- Lung cancer therapy including novel compounds and early phase trials
- Breast cancer therapeutics including novel compounds and early phase trials
- Health services research
- Economics of lung cancer therapy
- Treatment decision-making in advanced cancer, including development of patient decision aids
- Patient-physician communication
Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer.
Cancer Med. 2019 Oct 24;:
J Thorac Dis. 2019 Sep;11(Suppl 15):S1877-S1880
Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.
Curr Oncol. 2019 Aug;26(4):e551-e557
A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer.
ESMO Open. 2019;4(4):e000532
Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population-based reflex testing.
Cancer. 2019 Aug 07;:
Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis.
Mol Carcinog. 2019 Jul 29;:
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Lung Cancer. 2019 Aug;134:259-267
Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer.
Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1228-1237
Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group ...
Lung Cancer. 2019 Jul;133:48-55
Clinician Investigator, Princess Margaret Cancer Centre
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
President, Lung Cancer Canada
Chair, Working Group on Economic Analysis, National Cancer Institute of Canada Clinical Trials Group